Greziprubart clinical trials
How each study uses greziprubart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the greziprubart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- STSA-1002 Injection
- 6
Studies by the year they started
7 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
STSA-1005 (1)
Studies
Open first, then newest update. How each study uses greziprubart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress SyndromeRecruitingPhase 3Staidson (Beijing) Biopharmaceuticals Co., LtdNCT07208591Written as STSA-1002 injection
- To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress SyndromeCompletedPhase 1/2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT06038916Written as STSA-1002 Injection
- A Study of STSA-1002 Combined With STSA-1005 in Healthy SubjectsTerminatedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05559125Written as STSA-1002 Injection
- The Safety of STSA-1002 Following Intravenous Infusion in Healthy SubjectsCompletedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05166837Written as STSA-1002 injection
- The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy SubjectsCompletedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05702983Written as STSA-1002 subcutaneous injection
- A Study of STSA-1002 in Healthy SubjectsCompletedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05497635Written as STSA-1002 Injection
- The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy SubjectsCompletedPhase 1Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05032144Written as STSA-1002 injection
Codes
What other systems call greziprubart · ClinicalTrials.gg INT018714
- UNII (FDA) ZQL8925JUBGREZIPRUBARTOne source FDA
- NCI Thesaurus C211833GreziprubartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZQL8925JUB | GREZIPRUBART | One source FDA |
| NCI Thesaurus | C211833 | Greziprubart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.